Clinical trials: Tuberculosis, Pulmonary, open to volunteers
Tuberculosis, Pulmonary
DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
The goal of this observational study is to investigate whether model-informed precision dosing (MIPD), as a clinical support for early individualised dosing in addition to the national TB care program, can optimise the drug…
- Trial name
- DoseTB (NCT06585358)
- Testing
- MIPD
- Where
- 2 sites in Sweden
- Volunteers
- 30 people
- Sponsor
- Karolinska Institutet
Tuberculosis, Pulmonary
Tuberculosis Cohort Avicenne Hospital
Tuberculosis represents the second highest death rate from an infectious disease in the world, just after COVID-19. The most affected department of France is Seine-Saint-Denis.
- Trial name
- COTB-AVC (NCT05539014)
- Testing
- Data collection
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Post Tuberculosis
Mechanisms, Biomarkers and Pulmonary Rehabilitation in Post-TB Lung Disease
Tuberculosis (TB) affects millions of people worldwide, and many individuals continue to experience long-term health problems even after completing TB treatment.
- Trial name
- AFTER-TB (NCT07731009)
- Testing
- Pulmonary rehabilitation
- Volunteers
- 760 people
- Sponsor
- Jose Antonio Dominguez Benitez
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Pulmonary Disease, Pulmonary Infection
A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM) is increasing worldwide, and this trend has been confirmed in Korea.
- Conditions
- Pulmonary Disease, Pulmonary Infection, Non-Tuberculous Mycobacterial Pneumonia
- Trial name
- NTM-KOREA (NCT03934034)
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Hospital
Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with…
- Trial name
- NCT07228702
- Testing
- Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Vancouver Coastal Health
Non-Tuberculous Mycobacterial Pneumonia
Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis
This study evaluates a diagnostic serological test for Non-Tuberculous Mycobacteria (NTM) infection in cystic fibrosis patients by measuring T cell response.
- Trial name
- MUCEM (NCT06602869)
- Testing
- Scheduled visit (V1)
- Where
- France
- Volunteers
- 76 people
- Sponsor
- University Hospital, Montpellier
Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM)
A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
The treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate.
- Conditions
- Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid
- Trial name
- NCT07191834
- Volunteers
- 60 people
- Sponsor
- Wuhan Pulmonary Hospital
Tuberculosis, Latent Tuberculosis
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
- Trial name
- LIMBO-TB (NCT06526689)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Mycobacterium Tuberculosis, Tuberculosis, Pulmonary
Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
Tuberculosis (TB) is a leading infectious cause of death worldwide. Current strategies for monitoring TB treatment response are culture dependent and insensitive.
- Conditions
- Mycobacterium Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Extra-Pulmonary
- Trial name
- Mtb-Dynamic (NCT06845618)
- Where
- Thailand
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis, Pulmonary
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
A phase 2, two-part, multicentre, open label, controlled, randomised clinical trial in adult participants with newly diagnosed, sputum-positive pulmonary drug-sensitive tuberculosis (DSTB).
- Trial name
- SYNERGY (NCT07773610)
- Testing
- TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab
- Where
- South Africa
- Volunteers
- 135 people
- Sponsor
- TASK Applied Science
Tuberculosis, Pulmonary
Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis.
- Trial name
- NCT07830771
- Testing
- [18F]-FAPI-74
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
COPD, Interstitial Pneumonia
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
This study analyzes patients who underwent lung transplantation at the First Affiliated Hospital of Zhejiang University from 2017 to 2024, focusing on anesthesia's impact on post-op results.
- Conditions
- COPD, Interstitial Pneumonia, Bronchiectasis, Respiratory Failure
- Trial name
- NCT06922916
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Zhejiang University
Mediastinal Lymphadenopathy, Lung Cancer
Mediastinal EBUS Cryobiopsy Study In Sweden
This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other.
- Conditions
- Mediastinal Lymphadenopathy, Lung Cancer, Sarcoidosis, Lymphoma
- Trial name
- MECRIS (NCT06347939)
- Testing
- Mediastinal lymph nodes cryobiopsies
- Where
- 2 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis Lung
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M.
- Trial name
- BioMol-MA (NCT06413459)
- Testing
- Luminex; scRNAsec
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale San Raffaele
Tuberculosis, Pulmonary
Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis.
- Trial name
- NCT07271225
- Testing
- Press Needle
- Where
- Indonesia
- Volunteers
- 58 people
- Sponsor
- Universitas Indonesia
to Assess Effect of Peer-led Education
Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia
The study might come up with valuable findings to address poor treatment outcome, poor quality of life, disability score and depressive symptoms. The findings may also be decreased health professional workload.
- Trial name
- DS-PTB (NCT07387601)
- Testing
- peer-led education
- Where
- Ethiopia
- Volunteers
- 250 people
- Sponsor
- Bahirdar University
Tuberculosis, Tuberculosis Infection, Latent
Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan
RIFA-REAL is a prospective observational longitudinal study evaluating the safety, feasibility, and effectiveness of rifapentine-based shorter treatment regimens for drug-susceptible tuberculosis (DS-TB) and tuberculosis…
- Conditions
- Tuberculosis, Tuberculosis Infection, Latent, Tuberculosis, Pulmonary, Drug Sensitive
- Trial name
- RIFA-REAL (NCT07668479)
- Volunteers
- 350 people
- Sponsor
- Public Union "Kazakhstan Association of Phthisiopulmonologists"
Tuberculosis, Acute Coronary Syndrome
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD).
- Conditions
- Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)
- Trial name
- Doxy-TB (NCT05473520)
- Testing
- Doxycycline
- Where
- 6 sites in Malaysia, Singapore
- Volunteers
- 150 people
- Sponsor
- National University Hospital, Singapore
Tuberculosis-related Obstructive Pulmonary Disease
Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis
Tuberculosis-related obstructive pulmonary disease (TOPD), as a high-burden disease in most countries, poses difficulties in the diagnosis and treatment of the disease when coexisting, and increases the risk of death for…
- Trial name
- NCT06676800
- Testing
- Yiqi Gubiao pill
- Volunteers
- 74 people
- Sponsor
- Fourth Affiliated Hospital of Xinjiang Medical University